Myriad Genetics, Inc. (MYGN) Stock Forecast
MYGN analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 2.78 / 5 from 9 analysts
- Price target
- $4.11 average of analyst targets
- Upside to target
- +3.3% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.25
- 52-week range
- $2.86 – $8.18
MYGN analyst ratings
9 analystsNumber of analysts at each rating.
MYGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MYGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.27 | −$0.15 | $0.00 | 0.0% | 8 |
| Current fiscal year (2026) | −$0.74 | −$0.89 | −$0.58 | $0.06 | −1,331.8% | 9 |
| Next fiscal year (2027) | −$0.59 | −$0.76 | −$0.46 | −$0.74 | +20.3% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MYGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $191.3M | $188.6M | $192.6M | −7.0% | 8 |
| Current fiscal year (2026) | $777.9M | $772.7M | $784.0M | −5.7% | 9 |
| Next fiscal year (2027) | $820.5M | $805.5M | $845.1M | +5.5% | 9 |
MYGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MYGN revenue: reported and forecast
MYGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.07 | −$0.18 | −$0.21 | −$0.20 | −$0.20 | −380.7% | 0 up · 8 down |
| Current fiscal year (2026) | $0.05 | −$0.70 | −$0.75 | −$0.74 | −$0.74 | −1,646.2% | 0 up · 0 down |
| Next fiscal year (2027) | $0.15 | −$0.53 | −$0.57 | −$0.58 | −$0.59 | −489.6% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MYGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MYGN beat in 8 of 12.
What analysts expect from MYGN
9 analysts cover Myriad Genetics; their consensus rating is hold (2.78 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.11, 3.3% above the latest close of $3.98. Analysts expect earnings of −$0.74 per share for 2026, −1,331.8% from a year earlier. For 2027 the average estimate is −$0.59 per share on revenue of $820.5 million. Myriad Genetics beat the EPS estimate in 8 of the last 12 quarters.
Related: MYGN income statement, MYGN key metrics, MYGN chart. See the MYGN stock overview for the latest quote and news.
MYGN forecast FAQ
What is Myriad Genetics's price target?
The average analyst price target for Myriad Genetics is $4.11, 3.3% above the latest close of $3.98.
Is Myriad Genetics a buy, hold or sell?
Of 9 analysts covering Myriad Genetics, 1 rate it a strong buy, 0 a buy, 5 a hold, 2 a sell and 1 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Myriad Genetics's EPS forecast?
Analysts forecast −$0.74 per share for 2026 (range −$0.89 to −$0.58); for 2027 the estimate is −$0.59.
What is Myriad Genetics's revenue forecast?
The average revenue estimate for 2026 is $777.9 million, growth of −5.7%; for 2027 it is $820.5 million.
When does Myriad Genetics report earnings?
Myriad Genetics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.25.
Does Myriad Genetics usually beat earnings estimates?
Myriad Genetics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.